KBL Merger Corp. IV
Status: Closed Deal
U=S+W+R
W=S/2@11.5
R=S/10
| IPO Proceeds, $M | $115.00M |
|---|---|
| IPO Date | Jun 2, 2017 |
| CEO | Marlene Krauss, M.D. |
| Left Lead | Ladenburg Thalmann |
| IPO Cash in Trust | 101.4% |
| SPAC Tenor | 18+3+3+3+3+4+3+4 |
| IPO Sector | Healthcare ▶ |
| IPO Geography | Global |
| Target Company | 180 Life Sciences |
| Deal Announced | Jul 26, 2019 |
| Deal Size, $M | $242.90M |
| Deal Sector | Healthcare |
| Deal Geography | US/Canada |
| SEC Filings |
www.sec.gov 
|
| Approval Vote | Oct 26, 2020 |
| Amendment Vote | TBD |
| Closing Date | Nov 6, 2020 |
Formerly KBLM
ATNF
ATNFW
| Price | $0.86 $0.00 |
|---|---|
| Last closing price | $0.90 |
| H/L, today | $0.87 / $0.90 |
| H/L, 52-week | $0.36 / $11.14 |
| Volume, today | 19,283 |
| Volume, 3-month avg. | N/A |
Sign up for Free Trial
No credit card required
Sign in to view structure, cap table, and calendar of events.